ADM and cancer: However, in pancreatic adenocarcinoma (PAAD), ADM expression showed considerable fluctuation across stages, while in lung adenocarcinoma (LUAD) and liver hepatocellular carcinoma (LIHC), a downregulation of ADM expression was observed in stage IV, potentially due to the limited sample size in the advanced stages of these cancer types.